Through the activation of the mammalian target of the rapamycin (mTOR) pathway, anti-inflammatory TAMs downregulate their glucose metabolism which further perpetuates their anti-inflammatory phenotype and increases glucose availability for cancer cells to utilise, thus promoting tumour proliferation and progression [15,111]. The gene discussed is MTOR; the disease is cancer.